CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Celularity Inc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026
$1.16−0.09 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Celularity Inc revenue by segment
By business segment
| Revenue | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Degenerative Disease [Member] | $2.10M | $1.61M | $2.24M | $3.70M | $9.75M | $16.16M | $8.00M | $10.83M | $13.39M | $10.73M | $2.36M | $1.66M | 54.7% | -78.4% |
| Biobanking [Member] | $1.25M | $1.30M | $1.45M | $1.28M | $1.41M | $1.28M | $1.29M | $1.28M | $1.29M | $1.38M | $1.43M | $1.28M | 32.5% | -11.2% |
| Cell Therapy [Member] | $493.00K | $1.19M | $1.59M | $759.00K | $264.00K | – | – | – | – | – | – | – | 12.8% | +86.7% |
By product or service
| Revenue | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Royalty and Other [Member] | $1.73M | $1.92M | $2.94M | $2.08M | $1.00M | $7.71M | $4.61M | $870.00K | $551.00K | $1.22M | $675.00K | $754.00K | 45.0% | +73.0% |
| Service [Member] | $1.25M | $1.30M | $1.45M | $1.28M | $1.41M | $1.28M | $1.29M | $1.28M | $1.29M | $1.38M | $1.43M | $1.28M | 32.5% | -11.2% |
| Product [Member] | $866.00K | $884.00K | $894.00K | $2.38M | $9.02M | $9.14M | $3.39M | $9.96M | $12.84M | $9.52M | $1.68M | $906.00K | 22.5% | -90.4% |
| Processing and Storage Fees, Net [Member] | – | – | $1.45M | $1.28M | $1.41M | – | $1.29M | $1.28M | $1.29M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Celularity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.